Ludwig Enterprises Inc. Announces AI-Powered Cancer Screening Technology
Ludwig Enterprises Inc. (OTC PINK:LUDG) has announced Revealia™, an AI-powered cancer screening technology. This revolutionary mail-order non-invasive cheek swab test aims to transform early cancer detection with continuously improving accuracy. At its core is the Revealia Inflammatory Index (RII), which uses advanced AI to analyze mRNA-based genetic signals associated with cancer presence.
Developed by Dr. Kyle Ambert, PhD, Director of Data Science at Nike's Consumer Data Science Division, the AI technology employs machine learning algorithms that continuously update and improve as new patient data is received. Key features include optimization of sensitivity and specificity trade-offs, continuous learning from an expanding dataset, and analysis of mRNA samples from over 40 multipurpose medical clinics across the United States.
Ludwig Enterprises Inc. (OTC PINK:LUDG) ha annunciato Revealia™, una tecnologia per lo screening del cancro supportata dall'IA. Questo rivoluzionario test non invasivo con tampone buccale da ordinare per posta punta a trasformare la diagnosi precoce del cancro con un'accuratezza in continua evoluzione. Al centro c’è il Revealia Inflammatory Index (RII), che utilizza un'IA avanzata per analizzare i segnali genetici basati su mRNA associati alla presenza di cancro.
Sviluppata dal Dr. Kyle Ambert, PhD, Direttore della Data Science presso la Divisione Science dei Dati dei Consumatori di Nike, la tecnologia IA impiega algoritmi di apprendimento automatico che si aggiornano e migliorano continuamente man mano che vengono ricevuti nuovi dati sui pazienti. Le funzionalità chiave includono l'ottimizzazione dei compromessi tra sensibilità e specificità, l'apprendimento continuo da un dataset in espansione e l'analisi di campioni di mRNA provenienti da oltre 40 cliniche mediche multifunzionali negli Stati Uniti.
Ludwig Enterprises Inc. (OTC PINK:LUDG) ha anunciado Revealia™, una tecnología de detección de cáncer potenciada por IA. Esta revolucionaria prueba no invasiva con hisopo bucal por correo tiene como objetivo transformar la detección temprana del cáncer con una precisión en constante mejora. En su núcleo se encuentra el Revealia Inflammatory Index (RII), que utiliza inteligencia artificial avanzada para analizar señales genéticas basadas en mRNA asociadas con la presencia de cáncer.
Desarrollada por el Dr. Kyle Ambert, PhD, Director de Ciencia de Datos en la División de Ciencia de Datos del Consumidor de Nike, la tecnología de IA emplea algoritmos de aprendizaje automático que se actualizan y mejoran continuamente a medida que se reciben nuevos datos de pacientes. Las características clave incluyen la optimización de los compromisos entre sensibilidad y especificidad, el aprendizaje continuo de un conjunto de datos en expansión y el análisis de muestras de mRNA de más de 40 clínicas médicas multifuncionales en los Estados Unidos.
루드비히 엔터프라이즈 Inc. (OTC PINK:LUDG)는 AI 기반의 암 검진 기술인 Revealia™를 발표했습니다. 이 혁신적인 우편으로 주문하는 비침습적 볼 점막 테스트는 초기 암 발견을 지속적으로 개선되는 정확도로 변모시키는 것을 목표로 하고 있습니다. 핵심은 Revealia 염증 지수 (RII)로, 이는 암 존재와 관련된 mRNA 기반 유전 신호를 분석하기 위해 고급 AI를 사용합니다.
이 기술은 Dr. Kyle Ambert, PhD, 나이키 소비자 데이터 과학 부문 데이터 과학 이사가 개발했으며, AI 기술은 새로운 환자 데이터가 수신될 때마다 지속적으로 업데이트되고 개선되는 기계 학습 알고리즘을 사용합니다. 주요 기능에는 민감도와 특이도의 균형 최적화, 확장된 데이터 세트로부터의 지속적인 학습, 미국 내 40개 이상의 다목적 의료 클리닉에서의 mRNA 샘플 분석이 포함됩니다.
Ludwig Enterprises Inc. (OTC PINK:LUDG) a annoncé Revealia™, une technologie de dépistage du cancer alimentée par l'IA. Ce test non invasif par écouvillon buccal à commander par courrier vise à transformer la détection précoce du cancer grâce à une précision en amélioration continue. Au cœur de cette technologie se trouve le Revealia Inflammatory Index (RII), qui utilise de l'IA avancée pour analyser des signaux génétiques basés sur l’ARNm associés à la présence du cancer.
Développée par Dr. Kyle Ambert, PhD, Directeur de la Science des Données chez Nike, la technologie IA utilise des algorithmes d'apprentissage machine qui se mettent à jour et s'améliorent continuellement à mesure que de nouvelles données de patients sont reçues. Les fonctionnalités clés comprennent l'optimisation des compromis entre sensibilité et spécificité, l'apprentissage continu à partir d'un ensemble de données en expansion et l'analyse des échantillons d'ARNm provenant de plus de 40 cliniques médicales polyvalentes à travers les États-Unis.
Ludwig Enterprises Inc. (OTC PINK:LUDG) hat Revealia™ angekündigt, eine KI-gestützte Technologie zur Krebsfrüherkennung. Dieser revolutionäre nicht-invasive Wangentest per Post zielt darauf ab, die frühe Krebserkennung mit ständig verbesserter Genauigkeit zu transformieren. Im Kern steht der Revealia Entzündungsindex (RII), der fortschrittliche KI zur Analyse von mRNA-basierten genetischen Signalen verwendet, die mit der Krebspräsenz verbunden sind.
Entwickelt von Dr. Kyle Ambert, PhD, Direktor für Datenwissenschaft bei der Consumer Data Science Division von Nike, verwendet die KI-Technologie maschinelles Lernen Algorithmen, die kontinuierlich aktualisiert und verbessert werden, sobald neue Patientendaten empfangen werden. Zu den wichtigsten Funktionen gehören die Optimierung von Sensitivitäts- und Spezifitäts-Kompromissen, das kontinuierliche Lernen aus einem expandierenden Datensatz und die Analyse von mRNA-Proben aus über 40 multifunktionalen medizinischen Kliniken in den Vereinigten Staaten.
- Introduction of Revealia™, a potentially revolutionary cancer screening tool
- AI-driven technology that continuously improves accuracy
- Non-invasive and convenient mail-order cheek swab test
- Analysis of mRNA samples from over 40 multipurpose medical clinics across the US
- None.
Revolutionary AI-driven cheek swab test poised to transform early cancer detection with continuously improving accuracy. Revealia™: A Breakthrough in Cancer Detection through Advanced AI and Machine Learning
SPARKS, NV / ACCESSWIRE / September 24, 2024 / Ludwig Enterprises, Inc. (OTC PINK:LUDG), a USA based biotechnology company is pleased to announce Revealia™, which is set to become the world's most convenient cancer screening tool. This simple mail-order non-invasive cheek swab has the potential to save lives by detecting early signs of cancer.
At the heart of Revealia™ is the Revealia Inflammatory Index (RII), a sophisticated method for quantifying cancer risk. The RII leverages cutting-edge artificial intelligence to analyze mRNA-based genetic signals associated with the presence of cancer.
This proprietary technology was developed by Dr. Kyle Ambert, PhD, Director of Data Science at Nike's Consumer Data Science Division. Our AI technology employs machine learning algorithms that continuously update and improve as new patient data is received. This approach allows for ongoing refinement of our cancer detection capabilities.
Key features of our AI approach include:
Optimization of the trade-off between sensitivity and specificity
Continuous learning from an expanding dataset
Analysis of mRNA samples from over 40 multipurpose medical clinics across the United States
Looking Ahead
"Ludwig has uncovered game-changing mRNA-based genetic signals associated with the presence of cancer," stated Marvin S. Hausman, MD, CSO. "As we prepare to launch Revealia™, we're excited about the potential impact of our AI-driven approach for early cancer detection."
Ludwig Enterprises continues to advance its mission of providing accessible, accurate, and non-invasive cancer screening tools to improve public health.
About Ludwig Enterprises, Inc.
Ludwig Enterprises, Inc., a pioneering biotechnology company, is at the forefront of mRNA genomics and machine learning AI technology. Our mission is to combat chronic inflammation, a key factor in diseases like cancer and heart disease that account for over
For more information please visit: http://www.ludwigent.com.
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Ludwig Enterprises Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.
CONTACT:
Ludwig Enterprises, Inc.
Marvin S. Hausman MD, CSO
marvin@ludwigent.com
www.ludwigent.com
Investor Relations
Resources Unlimited NW LLC
Mike Sheikh, Investor Relations
mike@resourcesunlimtedllc.com
Contact Information
Mike Sheikh
Investor Relations
mike@resourcesunlimtedllc.com
SOURCE: Ludwig Enterprises Inc
View the original press release on accesswire.com
FAQ
What is Revealia™ and how does it work for cancer screening?
Who developed the AI technology behind Revealia™ for Ludwig Enterprises (LUDG)?
What is the Revealia Inflammatory Index (RII) used in Ludwig Enterprises' (LUDG) cancer screening technology?
How does Ludwig Enterprises (LUDG) improve the accuracy of its Revealia™ cancer screening technology?
